Harvard School of Public Health (HSPH)
Trial Pipeline
Beat the Heat Boston
NCT06982339
Doulas as Environmental Educators and Partners Study
NCT06032143
Teaching Kitchen Multisite Trial
NCT05628649
Impact of Sunscreen Dispensers in Parks Visited by Teenagers
NCT05908435
Nurse-Family Partnership Impact Evaluation in South Carolina
NCT03360539
Improving Health and Environmental Health Literacy of Professionals
NCT05879666
Dietary Biomarkers Intervention Core
NCT05616585
An Evaluation of the Team Birth Project
NCT03529214
Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite
NCT03279185
Reducing Skin Cancer Risk in Childhood Cancer Survivors
NCT02046811
Study on Out of School Nutrition and Physical Activity Environments
NCT01396473
Nutrition, Immunology and Epidemiology of Tuberculosis
NCT00197704
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
What the Pipeline for Harvard School of Public Health (HSPH) Shows
According to the ClinicalTrials.gov registry, Harvard School of Public Health (HSPH) is linked to 12 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 8% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 58% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Harvard School of Public Health (HSPH) reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Harvard School of Public Health (HSPH) is Health Knowledge, Attitudes, Practice with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.